Drug intelligence / Profile preview

ITI-7000

Development stage: Discontinued
Lead developer: Immunomic Therapeutics
Modality: DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics

Overview

ITI-7000 is an investigational DNA-based cancer vaccine developed by Immunomic Therapeutics, Inc. It utilizes the company's proprietary UNITE (Universal Intracellular Antigen Transduction) nucleic acid platform to target the ErbB2/HER2 protein. The vaccine is designed to stimulate a robust immune response by activating anti-tumor CD4+ and CD8+ T cells and promoting the infiltration of activated CD8+ T cells into tumors. Although it showed promise in preclinical studies for treating HER2-expressing neoplasms and urogenital diseases, its development has been discontinued.

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on ITI-7000.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ITI-7000.

Explore the full profile